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ABSTRACT 
 
 
After transplantation, corticosteroid-resistant Idiopathic Nephrotic Syndrome (INS) 
rapidly recurs in 30-50% of recipients, suggesting the presence of (a) circulating factor(s) 
which alter(s) the glomerular filtration barrier. In this paper, we investigated the possible 
implication of the soluble ST2 protein (sST2), a product of the c-maf pathway and a marker 
of Th2 cells, in the development of INS recurrence, as an association between INS relapse 
and an atypical Th2 polarization involving activation of c-maf has recently been reported. We 
analyzed sST2 levels in the serum of kidney recipients with INS as their primary kidney 
disease but with (n=31) and without (n=40) recurrence after transplantation and of recipients 
with primary glomerular diseases different from INS (n=34). We found a significant increase 
of sST2 levels in the sera of patients suffering INS recurrence, but not in those of non-
recurrent INS and non-INS patients. No differences were detected in these sera before 
transplantation. Moreover, recurrent patients displayed the same sST2 isoform as the two 
control groups. In vitro, a mouse podocyte cell line was profoundly altered by incubation with 
sera of recurrent patients. However, purified sST2 from these patients was not able to 
reproduce these damages. In addition, induction of high sST2 levels in rats did not trigger 
proteinuria. Collectively, these data suggest that sST2 is a marker of INS recurrence that 
could be of interest for its diagnosis in ambiguous clinical situations. Nonetheless, sST2 does 
not seem to be directly implicated in INS development. 
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INTRODUCTION 
 
 
Idiopathic Nephrotic Syndrome (INS) is a glomerulopathy of unknown etiology 
characterized by a massive albuminuria without histological evidence of inflammatory injuries 
or immune complex deposits. Recently, genetic abnormalities have been shown to be 
involved in INS. However, patients with INS resistant to the treatments who progress to end-
stage renal failure with focal and segmental glomerular sclerosis (FSGS) usually do not 
exhibit gene alteration1,2. After transplantation, 30-50% of these patients develop a 
recurrence of their initial disease, leading to roughly 50% of graft lost3,4. In 90% of these 
patients, nephrotic syndrome recurs within the first hours after transplantation, suggesting 
the intervention of a circulating albuminuric factor. The beneficial effect of plasmapheresis 
also supports this hypothesis3-6. Several attempts have been made in order to determine the 
nature of this putative albuminuric factor, but its molecular characterization has remained 
elusive. We recently showed that the Buffalo/Mna rat strain spontaneously develop a 
nephrotic syndrome with a histological pattern closely similar to the human disease7. 
Moreover, we demonstrated the recurrence of proteinuria in Buffalo/Mna recipients of a 
normal rat kidney whereas nephrotic Buffalo/Mna kidneys recovered albuminuric 
permselectivity after transplantation in a normal recipient, suggesting the presence of extra 
renal factor(s) and making this strain the first possible relevant model of the human disease8. 
 The recent observation of an association between INS relapse and an atypical Th2 
polarization, characterized by c-maf activation and IL-4 down regulation9, raises the question 
of implication of T cells in the pathophysiology of this disease. In this work, we have 
investigated the role of a putative soluble factor, sST2, whose promoter contains the c-maf 
recognition element (MARE) (DS, unpublished), as a candidate in the narrow but much 
selected population of INS recurrent patients after transplantation. In human, the ST2 gene 
encodes for two main products by alternative splicing: a transmembrane protein called ST2L, 
which is composed of an extracellular region with three immunoglobulin domains and of an 
intracellular toll-interleukin-1 receptor (TIR) domain, and a soluble secreted protein, sST2, 
which only includes the extracellular part of ST2L. The soluble form is secreted by activated 
Th2 cells which express ST2L at their surface10. In mice models, the ST2 protein has been 
described as a stable marker of a subset of activated Th2 cells independent of the production 
of IL-4, IL-5 and IL-1011, although it is not an universal marker of this T cell phenotype. 
Several investigations have reported an important role for ST2 in allergic airway 
inflammation12-14, and it is well known that there is a relationship between respiratory allergy 
and proteinuria in some cases of nephrotic syndrome. We and other authors have showed 
that ex vivo immunoadsorption of the plasma of patients with recurrent nephrotic syndrome 
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onto protein A or anti-human immunoglobulin columns transiently decreases or abolishes 
proteinuria15. Interestingly, it has been found that the ST2 protein binds these proteins in vitro 
(DS, unpublished). The fact that sST2 is both associated with Th2 biased immune response 
and that this protein also binds to protein A makes it a candidate for a role in INS pathology 
and particularly in recurrence. 
In this paper, we investigate the possibility of a role of sST2 in INS recurrence in 
human recipients with INS recurrence as well as in Buffalo/Mna rats. We report that INS 
recurrence after transplantation is strongly associated with an overexpression of the sST2 
protein in recipients’ blood, reinforcing the observation of a Th2 polarization associated with 
INS. Nonetheless, we were not able to demonstrate that sST2 directly affects the glomerular 
filtration barrier in vivo, or that this factor is responsible for the podocyte cell line alteration 
induced by sera from recipients with INS recurrence. Collectively, our results suggest that an 
elevated sST2 level is a marker for INS recurrence after transplantation in human that may 
be useful for its diagnosis in ambiguous clinical situations. 
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RESULTS 
 
High sST2 levels are associated with INS recurrence after renal transplantation: 
sST2 serum concentrations were measured before and after renal transplantation in 
three clinical situations: 1/ patients with INS recurrence, 2/ patients with INS non-recurrence 
and 3/ patients with non-INS disease on native kidneys and who displayed high proteinuria 
levels from different origins after transplantation. The clinical characteristics of these patients 
are summarized in Table 1. We did not detect significant differences in serum sST2 
concentrations between these three cohorts before transplantation (Figure 1). In contrast, 
sST2 levels were strongly increased in recurrent patients after transplantation (median = 
617.5 pg/mL vs. 124 pg/mL before transplantation, P < 0.01), while they remained low in the 
comparison in the non-recurrent group (median = 23 pg/mL, P < 0.001) and in the group of 
patients without INS (median = 158.5 pg/mL, P < 0.01). 
Determination of the capacity of sST2 concentrations to distinguish INS recurrence 
and INS non-recurrence by ROC curve analysis (Figure 2A) revealed an excellent 
discriminative power (AUC = 0.9, 95% confidence interval 79% - 99%), with a sensitivity of 
80% and a specificity of 97% at a cut-off value of 205 pg/mL of circulating sST2. The ROC 
curve analysis was then applied to compare patients with INS recurrence and patients with 
non-INS glomerular diseases, who both displayed similar proteinuria levels after 
transplantation. As shown in figure 2B, sST2 levels also discriminated these two cohorts 
(AUC = 0.75, 95% confidence interval 59% - 89%), with a sensitivity of 55% and a specificity 
of 86% at a cut-off value of 602 pg/mL of serum sST2. 
Altogether, these results point out that post-transplantation recurrence is tightly 
associated with an upregulation of sST2 in patients with INS, and that measurement of sST2 
levels in proteinuric patients after transplantation could discriminate recurrent patients from 
the others. Moreover, these observations raise the question of a potential involvement of the 
sST2 protein in the development of this disease. 
 
Recipients with recurrent INS do not accumulate a specific sST2 isoform: 
The possibility of an abnormal sST2 isoform was suggested by the absence of 
proteinuria in some patients with high sST2 levels (allergic diseases). sST2 immunopurified 
from the plasma of a patient with INS recurrence and a high sST2 level was analyzed by 
bidimensional electrophoresis (Figure 3). Several clusters of spots were detected, but only 
three of them had a degree of intensity allowing the analysis. The cluster #1 presented the 
same characteristics as those described for sST2 of the “normal” human serum, i.e. a 
molecular weight of 57 kDa and an isoelectric point of 8.40 (as described in the SwissProt-
Expasy database). The two other clusters had only one feature closed to the normal sST2 
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protein: the isoelectric point for the cluster #2 (approximately 8.00), and the molecular weight 
for the cluster #3 (about 60 kDa). These three clusters were therefore analyzed by mass 
spectrometry (LC-ESI-MS/MS). Upon sequencing, the sST2 protein was detected only in the 
cluster #1 (Table 2), presenting all the expected characteristics and electrophoretic behavior, 
suggesting that recurrent patients display the normal isoform of the sST2 protein. 
 
Sera from patients with INS recurrence but not sST2 induce podocyte cell line injury in 
vitro: 
An immortalized mouse podocyte cell line 16 was used to investigate whether the 
serum and purified sST2 of recurrent patients could alter morphological and/or functional 
characteristics of podocytes. Incubation of these cells with serum or plasma from recurrence 
induced cell body contraction, nucleus retraction and loss of cell processes (Figure 4), 
whereas the cell morphology was well conserved in podocytes exposed to serum from non-
recurrence, confirming a previous report17. However, we found these modifications with only 
70% of the sera from recurrence tested, which may point out a limit in the sensitivity of this 
test. In contrast, we found no podocyte injury after incubation with sera from patients without 
recurrence. Analysis by dual-labelling immunofluorescence of the cell distribution of F-actin 
and vinculin showed some major architectural modifications of podocytes incubated with 
reactive sera from recurrent patients. Indeed, incubated podocytes exhibited a considerable 
redistribution of actin filaments around the nucleus, with a rarefaction of cortical actin and a 
scarce expression of vinculin (Figure 4B). In contrast, podocytes incubated with serum from 
patients with non-recurrence displayed a normal phenotype. Altogether, these results support 
the concept that serum and plasma of INS recurrent patients contain factor(s) capable to 
directly induce podocytes morphological damages. 
In order to determine whether the sST2 protein was implicated in the podocyte 
injuries we observed in vitro, we purified sST2 from reactive plasmas and tested the activity 
of the different fractions (initial plasma, plasma sST2-depleted and purified sST2 protein) on 
differentiated podocytes. We found that podocytes exposed to sST2-depleted plasma 
exhibited the same architectural modifications than podocytes incubated with the primitive 
plasma (Figure 5). Furthermore, podocytes exposed to sST2 proteins purified from the same 
samples displayed a normal phenotype, showing that sST2 is not the serum toxic fraction in 
recurrent patients.  
 
Achieving high sST2 circulating levels does not trigger proteinuria in rat: 
Because the absence of in vitro effect of sST2 on the mouse podocyte cell line does 
not necessarily exclude a role for sST2 in INS recurrence, we also investigated whether this 
protein could induce proteinuria and glomerular damages in rat. To do so, we used two 
 7
experimental approaches. First, we treated Sprague-Dawley rats with an adeno-associated 
virus coding for the human sST2 protein. Administration of this AAV intravenously did not 
induce proteinuria in these rats (Figure 6B), despite induction of high circulating sST2 levels 
(Figure 6A). Second, we injected directly into the renalry of healthy Lewis 1W rat the totality 
of sST2 purified from the blood of another Lewis 1W rat or of a nephrotic Buffalo/Mna rat in 
order to focus as much as possible the potential effects of this protein on the kidney. Figure 7 
shows that the increase in blood concentration of sST2 was not associated with an increase 
in urinary protein. This was the case both for injection of sST2 purified from Lewis 1W rats or 
from Buffalo/Mna rats. 
Altogether, these results do not suggest that sST2 acts directly on the kidney to 
induce the development of INS recurrence after transplantation. 
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DISCUSSION 
 
Idiopathic Nephrotic Syndrome is a heterogeneous disease. In non genetic forms, the 
primary disorder seems to involve the immune system. To date, little is known about immune 
mechanisms which ultimately lead to the disorganisation of the glomerular filtration barrier 
and since the first report of INS recurrence following renal transplantation, the 
pathophysiology of this disease has become a challenge for nephrologists18. It has been 
postulated for a long time that INS results from a T cell dysfunction, leading to the release of 
a circulating factor responsible for glomerular damages19. In this regard, INS patients with 
recurrence after transplantation represent an interesting “model” in which an immune origin is 
highly suggested. Over the past 30 years, several teams, including ours, attempted without 
success to identify a circulating factor in INS. On the basis of an active serum component 
binding to protein A affinity columns, we have suggested that the permeability factor displays 
some immunoglobulin-like properties6. These findings were also supported by Savin’s team 
which also suggested that a circulating factor with an apparent molecular weight around 50 
kDa5 binds to protein A. We first stated the hypothesis that the sST2 protein could be the 
factor, whose identity had been approached in these works, since it contains three Ig-like 
domains, binds with high affinity to protein A and displays a molecular weight of 57 kDa. In 
addition, a role for sST2 in INS recurrence was also suggested in a study using a subtractive 
cDNA library screening technique on peripheral blood mononuclear cells (PBMC), showing 
that the transcription factor c-maf was up regulated during INS relapse compared with 
remission9. Despite the fact that sST2 was not found increased in this previous study, this 
observation enables an interesting connexion with the ST2 protein, whose gene promoter 
contains the c-maf recognition element (MARE) (DS, unpublished). Moreover, several 
studies pointed out the ST2 protein as a selective marker of Th2 cells10-11, 20-21, which 
correlates with the atypical Th2 polarization described in INS22-24. Finally, sST2 seems to be 
tightly associated with allergic airways inflammation12-14, which have also been associated 
with some cases of nephrotic syndrome25-27.  
 
In this study, we reported that the sST2 production is strongly increased after 
transplantation in recipients with INS recurrence. In contrary, non-recurrent and non-INS 
patients have no elevated serum sST2 levels. On the basis of ROC analysis, we found that 
the recurrence phenomenon is significantly associated to sST2 concentrations after 
transplantation. Moreover, this up regulation does not correlate to the level of proteinuria 
(data not shown). This augmentation can not be due to the immunosuppressive treatment, 
known to raise Th2 responses, as the two other groups tested were also treated with 
calcineurin inhibitors and antimetabolic drugs. The use of corticosteroids was less frequent in 
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non-recurrent patients but was the same between INS recurrent patients and non-INS 
controls. Globally, these first experiments suggested that patients with a high blood sST2 
concentration after transplantation are likely undergoing INS recurrence. Unfortunately, we 
detected no difference between the tested groups before transplantation, precluding 
relevance of sST2 levels measurement as a predictability test for INS recurrence. 
Since increased production of sST2 appears associated with INS recurrence, we 
tested the hypothesis that this protein could be a permeability factor related to the 
development of INS. However, since sST2 is also increased in the sera of patients in acute 
pathological conditions such as myocardial infarction, sepsis, trauma or exacerbation of 
idiopathic pulmonary fibrosis28-30, all clinical situations not associated with proteinuria, the 
possibility of the existence of an abnormal sST2 isoform in recurrent INS patients was 
studied in a caricatural recurrent patient with a high circulating sST2 level. The bidimensional 
analysis of the sST2 protein purified from the plasma of this patient revealed the same 
isoform as described in healthy individuals. 
To further explore a putative role of sST2 in INS recurrence, the serum activity from 
recurrent and non-recurrent patients was tested on a mouse podocyte cell line before and 
after sST2 depletion, as well as the sST2 protein alone purified from these sera. As Saleem’s 
team which had underlined the toxic activity of nephrotic plasma on the human podocyte cell 
line17, we also found significant morphological damages in podocytes incubated with sera 
from patients with recurrence, whereas cells exposed to sera from non-recurrent patients 
exhibited a normal morphology. However, despite the serum activity was exclusively 
restrained to sera from patients with recurrence, we found a low sensitivity of this assay, as 
several sera from recurrent patients were not able to induce these podocyte damages. 
However, this could be due to the use of a mouse cell line with human sera, in contrary to 
Saleem who used human podocytes. Plasmas of recurrent patients, which presented an 
activity in vitro were then sST2-depleted and tested again on podocytes. Eluates containing 
purified sST2 proteins were not toxic, whereas the initial activity was present in sST2-
depleted plasmas. 
Finally, we tested the sST2 activity in vivo in Sprague-Dawley rats, using an adeno-
associated virus containing the human sST2 gene sequence. Despite a high and durable 
expression of the sST2 protein, these animals did not develop proteinuria. However, to avoid 
a specie specific effect, we also injected the sST2 protein purified from healthy Lewis 1W or 
nephrotic Buffalo/Mna rats sera directly in the renal artery of Lewis 1W rats. Nevertheless, 
these animals did not develop proteinuria, whether the sST2 proteins came from Lewis 1W 
or sST2 from Buffalo/Mna rats, further suggesting that this protein alone is not capable to 
induce kidney damages. 
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Altogether, these results showed that although sST2 is strongly increased in recurrent 
INS patients after transplantation, this protein does not seem to be directly implicated in the 
development of nephrotic proteinuria. sST2 is known to be strongly upregulated in the sera of 
patients with various disorders associated with an abnormal Th2 response, including 
systemic lupus erythematosus, asthma and idiopathic pulmonary fibrosis30-32. In the case of 
INS recurrence, this augmentation might also not be the cause of the disease, but rather a 
reflection of an atypical Th2 activation. 
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PATIENTS, MATERIALS AND METHODS 
 
 
Patients: 71 patients suffering from biopsy proven corticosteroid resistant INS and who had 
undergone a kidney transplantation from September 1983 to April 2007 were included in this 
study. Patients who presented an immediate proteinuria after transplantation, persisting 
above 3g/d at one month, with a kidney graft biopsy showing minimal change 
glomerulonephritis or isolated FSGS lesions without other transplant specific lesion, were 
defined as recurrent patients (R, n=31). All patients were treated with an immunosuppressive 
regimen including calcineurin inhibitors (CNI) and antimetabolic drugs (Mycophenolate 
Mofetil or Azathioprin) and/or by plasmapheresis or immunoadsorption. Pre transplant sera 
were collected within the 12 hours before surgery, and kept frozen at -20°C. At post 
transplantation serum harvesting, recurrent patients presented a persistent proteinuria above 
2g/d. On the contrary, non-recurrent INS patients (NR, n=40) displayed less than 1g/d of 
proteinuria one week after transplantation, and remained below 0.5g/d at any times 
thereafter. The control group consisted of 34 proteinuric transplanted patients with non-INS 
related end stage renal failure (diabetes, uropathy, IgA glomerulonephritis, 
nephroangiosclerosis, chronic interstitial nephropathy, renal polykystosis) (Table 1). In this 
group, the proteinuria was related to different kidney graft lesions: allograft 
glomerulonephritis, recurrence of IgA nephritis or diabetes. 
All of these patients gave informed consent to this study according to French legislative 
guidelines. 
 
Quantification of human sST2 protein: The concentration of soluble ST2 protein in the 
sera of INS patients and controls was determined with a commercial enzyme-linked 
immunosorbent assay (ELISA, RD Systems) as per manufacturer’s instructions. The 
sensitivity of this test is 25 pg/ml. 
 
Purification of human or rat sST2: In human, ST2 immunoaffinity column was prepared by 
coupling 150 µg of anti-human ST2 antibody (R&D Systems) onto agarose beads, using 
sodium cyanoborohydride, as directed by Seize Primary Immunoprecipitation Kit instructions 
(Pierce). Plasmas from recurrent INS patients were filtered through 0.22 µm filters and 
passed through the immunoaffinity column using a peristaltic pump at a flow rate of 0.5 
mL/min. After washing with PBS, bound proteins were eluted in 0.1M glycine. Ten fractions 
of 250 µL were collected, pooled and subjected to trichloroacetic acid (TCA) precipitation 
before bidimensional electrophoresis, or neutralized by adding 10 µL of 1M Na2HPO4 for in 
vitro experiments. 
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In rats, serum was prepared from Lewis 1W or Buffalo/Mna rats blood and sST2 was purified 
as for human plasma using an immunoaffinity column prepared by coupling anti-rat ST2 
antibody (Santa Cruz Biotechnology) onto agarose beads. Elution fractions were collected in 
cellulose tubular membranes (molecular weight cut-off = 12000 D, Interchim), concentrated 
three-fold using polyethylene glycol (PEG) (molecular weight 35000 D, Merck), and dialyzed 
against PBS (3 changes) for 2 days. Purified sST2 from one animal (around 35 ng) was kept 
to be injected in the renal artery of one Lewis 1W rat. 
 
Bidimensional electrophoresis: Eluted fractions from the human ST2 immunoaffinity 
column were precipitated with 20% TCA, for 30 min on ice. After centrifugation at 14,000 rpm 
at 4°C for 15 min, the pellet was washed twice with 100% cold acetone, and the final pellet 
was rehydrated for 20 min in 180 µL of 8M Urea, 2% CHAPS (w/v), 50 mM dithiothreitol, 
0.2% Bio-Lyte 3/10 ampholytes (w/v) and 0.01% bromophenol blue (w/v) (Bio-Rad). The 
sample was loaded on an immobilized pH gradient gel strip (pH 3 to 10; Bio-Rad), and 
isoelectric focusing was conducted in the IPGphor system (Amersham Biosciences) using 
the following steps: 20 V for 12 h; 500 V for 1 h; 1000 V for 1 h; 6000 V for 4 h. Afterwards, 
the strip was equilibrated for 10 min at room temperature (RT) with equilibration buffer (50 
mM Tris-HCl pH 8.8, 6 M Urea, 30% Glycerol (v/v), 2% SDS (w/v)) containing 1% DTT (w/v), 
and then 10 min at RT with equilibration buffer containing 2% Iodoacetamide (w/v). The strip 
was sealed with 0.1% agarose containing 0.005% of bromophenol blue, at the top of a 10% 
SDS-PAGE precast gel (Bio-Rad), and electrophoresis was performed using a Criterion 
System (Bio-Rad) until the bromophenol blue reached the bottom of the gel. Finally, the gel 
was fixed and stained for 2 h in 25% ethanol, 10% acetic acid, 0.2% Comassie Blue, and 
destained in 25% ethanol, 10% acetic acid.  
 
Mass spectrometry: Spots of interest were manually excised from the gel. Proteins 
contained in these spots were submitted to trypsin digestion and their identity was confirmed 
by LC-ESI-MS/MS. Briefly, peptides were separated by high performance liquid 
chromatography (HPLC) on a 75 µm x 15 mm Pepmap C18 reversed-phase column and 
elution was performed with a gradient of acetonitrile/water 0.1% formic acid. Peptides were 
then submitted to sequencing on a Q-TOF Globa spectrometer and analyzed with OVNIp 
software (INRA, Nantes, France). Digestion, HPLC and sequencing were performed at the 
Biopolymers – Interactions – Structural Biology Platform at the INRA research center 
(Nantes, France). 
  
Mouse podocyte cell culture: A previously described conditionally immortalized mouse 
podocyte cell line16 was routinely maintained in RPMI-1640 medium (Sigma) containing 100 
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µg/mL streptomycin, 100 U/mL penicillin (Sigma) and 10% foetal calf serum (FCS, Abcys). 
Podocytes were propagated on collagen I-coated plates (RD Systems) at 33°C in the 
presence of 10 U/mL of recombinant mouse -interferon (R&D Systems). Removal of -
interferon and temperature switch to 37°C inactivated the SV40 T antigen and induced 
podocytes differentiation in 14 days. 
 
In vitro effect of plasmas and sST2 on podocytes: After day 14 of podocytes 
differentiation, FCS of the medium was substituted with the same concentration (10%) of 
human plasma or serum from INS patients with or without recurrence. Plasmas which had a 
significant effect on podocytes were also tested after immunoadsorption of the sST2 proteins 
they contained, in parallel with this purified sST2. After 48h of incubation, cells were fixed in 
4% paraformaldehyde for 20 minutes for immunofluorescence staining: after blocking 30 
minutes with 10% NGS, podocytes were stained with TRITC-labeled phalloidin (Sigma) for F-
actin cytoskeleton visualization, with a monoclonal anti-vinculin antibody (Sigma) and the 
appropriate FITC-conjugated secondary antibody for the detection of the points of contact 
between the actin cytoskeleton and the extracellular matrix, and with DAPI for nuclear 
staining. 
 
In vivo effect of sST2 in rat: 
Animals: Overexpression of sST2 was induced through an AAV in healthy male Sprague-
Dawley rats (Janvier, Le Genest Saint Isle, France), or by injection in healthy male Lewis 1W 
rats (Janvier, Le Genest Saint Isle, France) of the purified sST2 protein from other Lewis 1W 
rats or from nephrotic 6 months-old male Buffalo/Mna rats. The Buffalo/Mna strain 
maintained in our lab was originally kindly provided by Dr Saito (Central Experimental 
Institute, Nokawa, Kawasaki, Japan). At the time of experimentation, Buffalo/Mna rats 
displayed a proteinuria level between 0.4 and 0.8 g/mmol. The animal care was in 
accordance with our national institutional guidelines. 
 
Construction of the AAV8-hST2 vector: AAV8 vector expressing human sST2 (hST2) driven 
by the ubiquitous RSV promoter was generated in the pZA-RSV-WPRE vector. For that, 
hST2 cDNA fragment (995 bp) was removed from pEFBOS-hST233 using BstXI, blunted and 
ligated downstream the RSV promoter and the chimeric intron into pZA-RSV-WPRE cut by 
EcoRI and BamHI and blunt-ended to give the pZA-RSVhST2WPRE. AAV8 vector contains 
also the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) and SV40 
polyadenylation signal flanked by inverted tandem repeats (ITRs). Recombinant AAV8 were 
manufactured as described elsewhere34 and purified by cesium chloride density gradients 
followed by extensive dialysis against PBS. 
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Intra-arterial injection of purified rat sST2: Intra-arterial injection was chosen to optimize the 
exposure of the kidney to sST2 proteins. After measuring their preinjection proteinuria levels, 
animals were anesthetized with isofluorane, a right nephrectomy was performed, the aorta 
was clamped above and below the left renal artery and 600 µL of purified sST2 was slowly 
injected into the aorta left renal artery segment. Total time of ischemia was about 10 minutes. 
After recovering, rats were placed in metabolic cages in order to collect their urine 24 h after 
the injection, and to measure diuresis. Over-all, two groups of 5 rats received purified sST2 
from Lewis 1W and Buffalo/Mna. Control rats were injected with the same volume of an 
isotonic saline solution with the same procedure. 
 
Proteinuria measurements: Rats were placed in metabolic cages for 24 h with free access to 
water but without food pellets which could fall into the urine collector and contaminate the 
samples. The total urinary protein concentration (g/L) was measured by a colorimetric 
method using a Hitachi autoanalyser (Boehringer). The urinary creatinine (mmol/L) was 
measured by the Jaffé method. Proteinuria was expressed according to this formula: 
Proteinuria (g/mmol) = urinary proteins (g/L) / urinary creatinine (mmol/L). It was considered 
as abnormal when the value was above 0.2 g/mmol. 
 
 
Statistical analyses: The nonparametric Wilcoxon rank-sum test was used to compare 
sST2 levels between each cohort of patients. Receiver-Operating-Characteristic (ROC) curve 
analysis was performed with R software (http://www.r-project.org/) to determine the cut-off 
points of sST2 concentration in the serum that yielded the highest combined sensitivity and 
specificity in diagnosis of INS recurrence (see Figure 2 legend for explanations). 
For comparison of rats’ proteinuria levels before and at different points after injection 
of the AAV8-hST2 or purified sST2 protein, the Friedman test and a Dunn’s multiple 
comparison test were used. 
For each statistical test, P values under 0.05 were considered to be significant. 
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FIGURE LEGENDS 
 
Figure 1: Concentrations of soluble ST2 protein in the sera. The level of sST2 was 
measured by ELISA before and after transplantation in the sera of INS patients with (R, n=24 
and n=20) or without recurrence (NR, n=22 and n=29) and in the sera of proteinuric 
transplanted patients (non-INS, n=13 and n=22). Significantly higher levels of circulating 
sST2 are found in recurrent patients after than before transplantation, as well as vs. the other 
cohorts after transplantation. Statistical differences according to the Wilcoxon rank-sum test 
are presented: *** = P < 0.001; ** = P < 0.01. 
 
Figure 2: Capacity of sST2 to diagnose INS recurrence after transplantation. 
Receiver-Operator-Characteristic (ROC) curves enable a measurement of the ability of sST2 
to correctly distinguish patients with INS recurrence from patients with INS non-recurrence 
(A) or from proteinuric non-INS patients (B). The ROC is represented as a graphical plot of 
the sensitivity vs. (1 – specificity) as the discrimination threshold varies.  The sensitivity (or 
“true positive fraction”) represents the capacity of the test to distinguish patients with 
recurrence, and the sensitivity is its ability to detect non-recurrent or proteinuric control 
patients. Thus, (1 – specificity) is also called “false positive fraction”. Finally, the capacity of 
the test to discriminate recurrent and control patients is measured by the area under the 
ROC curve (AUC), with an AUC of 1.0 corresponding to a perfect test.  
 
Figure 3: Two-dimensional analysis of the sST2 protein in recurrence. Eluate obtained 
after immunoprecipitation of sST2 from the plasma of a recurrent INS patient was tested by 
bidimensional electrophoresis using a pH range of 3 to 10. Areas indicated on the gels were 
further analyzed by mass spectrometry. 
 
Figure 4: Effects of sera from INS patients with or without recurrence on podocytes in 
vitro. Differentiated podocytes were incubated with different sera. A final concentration of 
10% serum was applied to the cells for 48h. Representative panels for each experiment are 
indicated. (A) FCS alone. (B) Reactive serum from patient with INS recurrence. (C) Serum 
from patient with INS non-recurrence. Immunofluorescence double staining was performed 
with anti-F actin (red), anti-vinculin (green) antibodies and DAPI (blue) on podocytes 
following incubation with FCS (D), reactive serum from INS recurrence (E) and serum from 
INS non-recurrence (F). 
 
Figure 5: Effects of the different fractions from anti-sST2 column on podocytes in 
vitro. sST2 of reactive plasmas from INS recurrence was purified on an anti-sST2 column. 
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The activity of each fraction was tested on the podocyte cell line (10%, 48h). Representative 
panels for each experiment are shown. (A) FCS alone. (B) Initial plasma. (C) sST2-depleted 
plasma. (D) Purified sST2. Immunofluorescence with anti-F actin (red), anti-vinculin (green) 
antibodies and DAPI (blue) after incubation with FCS (E), initial plasmas (F), sST2-depleted 
plasmas (G) and purified sST2 proteins (H). 
 
Figure 6: Effects of the intravascular administration of AAV8-sST2 into healthy SPD 
rats. (A) Serum sST2 concentrations were measured by ELISA at different time points after 
injection. (B) Proteinuria levels were measured in urine after injection. Data are expressed as 
mean protein (g/L)/creatinine (mmol/L) ± SD (scale bars). 
 
Figure 7: Proteinuria after injection of purified sST2 into the rat vasculature. Urine was 
collected at different time points after injection. Data are expressed as mean protein 
(g/L)/creatinine (mmol/L) ± SD (scale bars). 
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TABLES 
Table 1. Clinical characteristics of INS patients with or without recurrence after 
kidney transplantation (Tx) and proteinuric controls (non-INS). 
 
 AFTER TRANSPLANTATION 
 
INS 
Recurrence 
n=31 
INS 
Non-recurrence 
n=40 
 
Non-INS 
n=34 
Gender 17M / 14F 22M / 18F 27M / 4F 
Mean age at Tx 
(years) 28.7 [18-52] 39 [12-58] 41 [20-58] 
Duration of HD 
(months) 37.8 [0-140] 38 [0-127] 31.4 [0-104] 
Transplantation 
Rank G1=26, G2=4, G3=1 G1=33, G2=6, G3=1 G1=30, G2=4 
Time after Tx 
(months) 14 [1-134] 38 [1-184] 60 [6-165] 
Serum  
creatinine 
(µmol/L) 
175 [80-420] 140 [74-228] 247 [116-435] 
Proteinuria 
(g/24h) 4.5 [2.5-10] 0.14 [0-0.46] 43 [3-6.2] 
IS regimen CNI + MMF or AZA 100% under CS 
CNI + MMF or AZA 
46% under CS 
All CNI + MMF or AZA 
But one AZA 
88% under CS 
 
HD: Hemodialysis, IS: Immunosuppressive, CNI: Calcineurin Inhibitors, MMF: Mycophenolate Mofetil, 
AZA: Azathioprin, CS: Corticosteroids. 
 
Patients were roughly matched for number of transplantations, HLA compatibility, pre-graft 
panel reactive antibodies, type of treatment, duration of delayed graft function and 
maintenance immunosuppressive therapy. Intrinsically to the definition of the group, INS 
recurrent patients were younger than non-INS patients (P<0.001) and their proteinuria levels 
were significantly higher compared to non-recurrent patients (P<0.0001). In addition, sera 
were obtained later after transplantation for non-INS patients (P<0.01) compared to recurrent 
patients, but their proteinuria levels remained similar. 
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Table 2. Sequence of peptides corresponding to the human sST2 protein identified by 
mass spectrometry in the cluster of spots #1.  
 
Sequences Start End Observed Mass (kD) 
QSWGLENEALIVR 23 35 758 
VFASGQLLK 65 73 481 
FLPAAVADSGIYTCIVR 74 90 927 
QSDCNVPDYLMYSTVSGSEK 108 127 1140 
SFLVIDNVMTEDAGDYTCK 164 182 1089 
DEQGFSLFPVIGAPAQNEIK 204 223 1080 
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Figure 2 
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Figure 3 
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Figure 7 
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